Taxanes act as vascular disrupting agents and increase rate of metastasis when combined with anti-angiogenic therapy
R. Nandigama, M. Kallius, K. Hemmen, D. Shaoli, J. Pinnecker, D. Ascheid, V. Burkhard, H. Ali, J. Rainer, D. Scheld, S. Herterich, A. Zernecke, O. Penack, S. Diller, K. Camphausen, S. Erguen, U. Shankavaram, K. Heinze, F. Escorcia, E. Henke
Abstract
Taxanes are known to have a profound effect on endothelial cells and the vasculature even at low doses. Here, we show that taxanes, rather than being anti-angiogenic, function more as vascular disrupting agents (VDAs), although they exert a different mechanism of vascular permeabilization when compared to traditional VDAs such as combretastatins. In the tumor context, this VDA-effect leads to a rapid vascular collapse and acute hypoxia. Concomitant treatment with anti-VEGF drugs aggravates hypoxia by blocking vasculogenic rescue mechanisms. While this results in a strong growth-suppressing effect on the tumor, it also increases its invasiveness and metastatic potential. We demonstrate that combination of anti-angiogenic drugs with taxanes blocks tumor reperfusion, intensifies intravasation of circulating tumor cells (CTCs) and strongly increases metastasis. Anti-VEGF drugs are commonly applied in combination with cytotoxic drugs including taxanes. Our findings have significant implications for the clinical use of this drug combination.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- The impact of tumor receptor heterogeneity on the response to anti-angiogenic cancer treatment
Ding Li, Stacey D. Finley·Integrative BiologyPeer-reviewed·Apr 1, 2018
- Effect of eribulin on angiogenesis and endothelial adhesion molecules.
A. Abbona, A. Falletta, … O. Garrone·bioRxiv·Oct 28, 2021
- Multiscale modeling of tumor adaption and invasion following anti-angiogenic therapy
Colin G. Cess, Stacey D. Finley·Computational and Systems OncologyPeer-reviewed·Feb 21, 2022
- Remodeling tumor microenvironment by liposomal co-delivery of DMXAA and simvastatin inhibits malignant melanoma progression
V. F. Rauca, L. Patras, … M. Banciu·bioRxiv·Apr 26, 2021
- The antiangiogenic peptide VIAN-c4551 inhibits lung melanoma metastasis in mice by reducing pulmonary vascular permeability
Alma Lorena Perez, Magdalena Zamora, … Carmen Clapp·PLoS ONEPeer-reviewed·May 28, 2025
- The delivery of nano-formulated drugs to solid tumours is selectively increased by co-application of the vascular disrupting agent CA4P
Annabel Kitowski, Constanze Heise, … Julia Thorn‐Seshold·British Journal of PharmacologyPeer-reviewed·May 3, 2026